Hospital admissions · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · Adolescents with psychosis
It is very uncertain whether COMPUTER‐ASSISTED COGNITIVE REMEDIATION PROGRAMME (CACR) changes leaving the study early: For any reason compared with COMPUTER GAMES (CG, all short‐term) (very low certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to GM-CSF typically bone pain, nausea, fever and headache; not reported as serious; reporting poor and inconsistent (SoF comments cell, not GRADE-rated)
8 studies
GRADE not reported
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (severe) compared with placebo or no treatment (low certainty).
3 findings from 1 review
RR 0.74 [0.33, 1.67]
3 studies · 235 participants
Low
RR 0.59 [0.05, 7.11]
2 studies · 65 participants
Very low
RR 0.31 [0.01, 7.09]
1 study · 29 participants
Very low
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Oral pain · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral pain (mean pain score, 0 to 10 scale) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) led to lower number of days of treatment with opioid analgesics compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (tube feeding) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (tube feeding) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) led to higher improvement in mucositis compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) showed no clear difference in time to heal mucositis (days) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review